Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

235
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
235
Positron Emission Tomography01:29

Positron Emission Tomography

5.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

Blood·2026
Same author

Synergistic Effects of IMP-1700, Ciprofloxacin, and X-Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial-Resistant Bacteria.

MicrobiologyOpen·2026
Same author

Autoradiography and preclinical PET studies with radiolabeled asyn-44 and ACI-12589 for imaging α-synuclein.

Journal of Parkinson's disease·2026
Same author

Advancing fibroblast activation protein inhibitors for targeted radioligand therapy: Strategies and innovations to increase tumor residence time.

European journal of medicinal chemistry·2026
Same author

In Vivo Comparison of Site-Specific and Site-Selective Methods for Pretargeted Imaging in a Murine Model of Colorectal Cancer.

Molecular pharmaceutics·2026
Same author

Friedel-Crafts-Type Electrophilic Radiocyanation of (Hetero)arenes.

Organic letters·2026

Related Experiment Video

Updated: Sep 9, 2025

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.5K

Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.

Marius Müller1,2, Nadia Bom Pedersen1,2,3, Vladimir Shalgunov2

  • 1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Medicinal Research Reviews
|September 1, 2025
PubMed
Summary

Astatine-211 (211At) targeted alpha therapy shows promise for advanced cancers. Research focuses on production, properties, and strategies to improve 211At radiopharmaceuticals for better cancer treatment.

Keywords:
(de)astatinationastatine‐211astatine‐211 radiochemistryastatine‐211 radiopharmaceuticalsradioligand therapy

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.1K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

542

Related Experiment Videos

Last Updated: Sep 9, 2025

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.5K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.1K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

542

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical chemistry
  • Oncology

Background:

  • Targeted radioligand therapy is a key strategy for advanced cancers.
  • Alpha-emitters offer potent cell-killing capabilities for micro-metastases.
  • Astatine-211 (211At) is a promising alpha-emitter due to its decay characteristics.

Purpose of the Study:

  • To review the production and physicochemical properties of 211At.
  • To outline strategies for 211At-astatination of radiopharmaceuticals.
  • To discuss methods for minimizing in vivo deastatination and overview clinical development.

Main Methods:

  • Review of existing literature on 211At production and radiolabeling.
  • Analysis of 211At decay properties and half-life (7.2 hours).
  • Discussion of challenges and solutions in 211At radiopharmaceutical development.

Main Results:

  • Various 211At-astatination strategies have been developed.
  • Challenges in 211At production, handling, and in vivo stability are identified.
  • Ongoing preclinical and clinical studies are exploring 211At-labeled agents.

Conclusions:

  • 211At-based radiopharmaceuticals hold significant potential for future cancer management.
  • Addressing scalability and in vivo stability are crucial for clinical success.
  • Demonstrating clinical benefits over longer-lived radionuclides is essential.